The latest price target for Sorrento Therapeutics (OTCEM:SRNE) was reported by Cantor Fitzgerald on November 2, 2022. The analyst firm set a price target for $5.00 expecting SRNE to rise to within 12 months (a possible 35614.29% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Sorrento Therapeutics (OTCEM:SRNE) was provided by Cantor Fitzgerald, and Sorrento Therapeutics initiated their overweight rating.

There is no last upgrade for Sorrento Therapeutics

There is no last downgrade for Sorrento Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sorrento Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sorrento Therapeutics was filed on November 2, 2022 so you should expect the next rating to be made available sometime around November 2, 2023.

While ratings are subjective and will change, the latest Sorrento Therapeutics (SRNE) rating was a initiated with a price target of $0.00 to $5.00. The current price Sorrento Therapeutics (SRNE) is trading at is $0.01, which is within the analyst’s predicted range.